|  | VEGF-A mRNA expression | VEGF-B mRNA expression | VEGFR2 mRNA expression | VEGFR3 mRNA expression | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  | (Number = 307) | (Number = 304) | (Number = 308) | (Number = 308) | ||||||||
 |  | Median | Range | P value | Median | Range | P value | Median | Range | P value | Median | Range | P value |
Age | <50 | 34.8 | (32.4-38.3) | 0.001 | 35.3 | (33.1-37.5) | <0.001 | 32.1 | (29.6-34.4) | 0.190 | 31.9 | (27.4-34.2) | 0.030 |
 | ≥50 | 35.3 | (28.2-38.3) |  | 35.7 | (27.5-38.0) |  | 32.2 | (29.2-34.5) |  | 32.1 | (29.1-34.4) |  |
Treatment group | E-T-CMF | 35.0 | (33.4-38.3) | 0.629 | 35.5 | (27.5-37.4) | 0.13 | 32.1 | (29.5-34.5) | 0.99 | 32.0 | (27.4-34.0) | 0.47 |
 | E-CMF | 35.1 | (28.2-38.3) |  | 35.5 | (32.4-38.0) |  | 32.1 | (29.2-34.4) |  | 32.1 | (29.1-34.4) |  |
Menopausal status | Premenopausal | 34.8 | (32.4-38.3) | 0.001 | 35.4 | (33.1-37.5) | 0.002 | 32.1 | (29.6-34.4) | 0.17 | 31.9 | (27.4-34.2) | 0.069 |
 | Postmenopausal | 35.3 | (28.2-38.3) |  | 35.7 | (27.5-38.0) |  | 32.3 | (29.2-34.5) |  | 32.1 | (29.1-34.4) |  |
ER/PgR status | Negative | 35.5 | (32.4-38.3) | <0.001 | 35.4 | (27.5-38.0) | 0.023 | 32.3 | (29.6-34.4) | 0.310 | 32.1 | (27.4-34.4) | 0.288 |
 | Positive | 34.9 | (33.1-38.0) |  | 35.6 | (33.4-37.6) |  | 32.1 | (29.2-34.5) |  | 32.0 | (29.1-34.4) |  |
HER2 statusa | Negative | 35.0 | (28.2-38.2) | 0.020 | 35.5 | (32.4-37.5) | 0.856 | 32.0 | (29.2-34.5) | 0.088 | 32.0 | (29.1-34.4) | 0.294 |
 | Positive | 35.4 | (33.4-38.3) |  | 35.6 | (27.5-38.0) |  | 32.4 | (29.5-34.4) |  | 32.4 | (27.4-34.4) |  |
Positive nodes | 0 to 3 | 35.0 | (32.4-38.1) | 0.97 | 35.4 | (33.7-37.2) | 0.51 | 32.0 | (30.3-34.1) | 0.42 | 31.9 | (30.0-34.2) | 0.35 |
 | ≥4 | 35.0 | (28.2-38.3) |  | 35.6 | (27.5-38.0) |  | 32.1 | (29.2-34.5) |  | 32.0 | (27.4-34.4) |  |
Tumor size | ≤2 | 34.9 | (28.2-38.0) | 0.13 | 35.7 | (33.4-36.9) | 0.140 | 32.2 | (29.6-34.3) | 0.44 | 32.2 | (27.4-34.4) | 0.43 |
 | 2-5 | 35.0 | (32.4-38.3) |  | 35.4 | (27.5-38.0) |  | 32.0 | (29.2-34.5) |  | 32.0 | (29.1-34.4) |  |
 | >5 | 35.3 | (33.1-37.9) |  | 35.5 | (33.1-37.6) |  | 32.2 | (29.5-34.0) |  | 32.1 | (29.4-34.1) |  |
Histological grade | I-II | 34.9 | (28.2-38.0) | 0.027 | 35.6 | (33.1-37.6) | 0.024 | 32.2 | (29.9-34.4) | 0.25 | 32.1 | (29.5-34.4) | 0.12 |
 | III-IV | 35.1 | (32.4-38.3) |  | 35.4 | (27.5-38.0) |  | 32.0 | (29.2-34.5) |  | 32.0 | (27.4-34.4) |  |
Adjuvant HT | No | 35.8 | (33.1-37.9) | 0.003 | 35.5 | (33.8-36.8) | 0.59 | 32.1 | (30.1-33.9) | 0.85 | 31.8 | (29.9-33.6) | 0.62 |
 | Yes | 34.9 | (28.2-38.3) |  | 35.5 | (27.5-38.0) |  | 32.1 | (29.2-34.5) |  | 32.0 | (27.4-34.4) |  |
Adjuvant RT | No | 35.4 | (32.4-37.9) | 0.17 | 35.4 | (33.4-37.2) | 0.72 | 32.0 | (30.1-34.1) | 0.52 | 31.9 | (29.4-33.9) | 0.48 |
 | Yes | 35.0 | (28.2-38.3) |  | 35.5 | (27.5-38.0) |  | 32.1 | (29.2-34.5) |  | 32.1 | (27.4-34.4) |  |